Highlights Novo Nordisk A/S

Equities

NOVO B

DK0062498333

Pharmaceuticals

Real-time Estimate Cboe Europe Other stock markets 04:34:51 2025-01-21 am EST			5-day change	1st Jan Change
565.40 ^DKK	+2.56%		-5.22%	-10.06%

Jan. 03	New Year, Soft Start
Jan. 03	BNP Paribas Exane Cuts Novo Nordisk PT, Maintains at Outperform	MT

Highlights

Sector Update: Health Care Stocks Decline Late Afternoon	Jan. 17	MT
Sector Update: Health Care Stocks Softer Friday Afternoon	Jan. 17	MT
Novo Nordisk's Ozempic, Wegovy Among Drugs Chosen for US Medicare Price Talks	Jan. 17	MT
Top Midday Stories: Novo Nordisk's Ozempic, Wegovy Among Drugs Chosen for US Medicare Price Talks; Supreme Court Allows TikTok Ban to Take Effect	Jan. 17	MT
Global markets live: Citigroup, GM, Meta, Apple, Novo Nordisk...	Jan. 17
Investerum Strategic Value declined 1.26 percent in December - increased in Novo Nordisk	Jan. 17	FW
Novo Nordisk's Ozempic, Wegovy Among Drugs Chosen for US Medicare Price Talks	Jan. 17	MT
EU Panel Starts Probe on Novo Nordisk Weight Loss Drugs' Links to Rare Eye Disease	Jan. 17	MT
Novo Nordisk Says Higher-Dose Wegovy Achieves Greater Weight Loss in Trial -- Update	Jan. 17	DJ
Novo Nordisk's Ozempic, Wegovy Among Drugs Chosen for US Medicare Price Talks	Jan. 17	MT
Novo Nordisk's Ozempic, Wegovy Among Drugs Selected for US Medicare Price Talks	Jan. 17	MT
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Friday Amid Better-Than-Expected Big Bank Earnings	Jan. 17	MT
Novo Nordisk Says Trial of Higher Dose Semaglutide Achieved Primary Endpoint	Jan. 17	MT
Novo Nordisk's Wegovy Achieves Weight-Loss of 20.7% at Higher Dose, Study Says	Jan. 17	DJ
Novo Nordisk Controlling Shareholder Looks to Double Catalent's Size Over Five Years	Jan. 17	MT
Novo Nordisk's Subcutaneous Weight-loss Drug Meets Primary Objective in Late-stage Trial	Jan. 17	MT
Novo Nordisk: successful weight-loss study	Jan. 17	CF
Novo Nordisk's Subcutaneous Semaglutide Lowers Weight by 20.7% in Phase 3b Study	Jan. 17	MT
Novo Nordisk reports strong weight loss with new drug dose	Jan. 17	FW
Novo Nordisk Announces Headline Results from STEP UP	Jan. 17	CI
Guggenheim Securities raises target price for Novo Nordisk to DKK 798 (795), reiterates Buy - BN	Jan. 17	FW
Novo Holdings looks to double Catalent size with eye on Trump US manufacturing focus	Jan. 16	RE
Lexaria Bioscience Receives Ethics Board Approval for Oral Liraglutide Pilot Study	Jan. 15	MT
Swedbank Robur Healthcare down 5.48 percent in December - continued decline in the healthcare sector	Jan. 15	FW
Strand Wealth Fund down 1.57 percent in December - Novo Nordisk weighed down	Jan. 15	FW

Become a member to access more news.

100% Free Registration

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Wegovy, Ozempic Targeted by US for Medicare Price Cuts

January 17, 2025 at 10:36 am EST

Cagrisema sends Novo Nordisk to the mat

December 20, 2024 at 06:20 am EST

NOVO NORDISK : CagriSema results are not worthy of panic

December 20, 2024 at 09:14 am EST